Skip to main content
Clinical Trials/NCT00190606
NCT00190606CompletedPhase 2

Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence

Eli Lilly and Company2 sites in 2 countries200 target enrollmentStarted: January 1, 2002Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
200
Locations
2
Primary Endpoint
Effectiveness of combined duloxetine and PFMT with combined placebo and imitation PFMT in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

Study Overview

Brief Summary

The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Between 18 and 75 years of age
  • •Confirmed pure genuine stress incontinence
  • •Have discrete episodes of incontinence
  • •Have pelvic organ prolapse of no greater than Stage II

Exclusion Criteria

  • •Positive urine culture at visit 1
  • •Had formal PFMT with instruction
  • •Use of MAOI or other excluded medications
  • •Use of any anti-incontinence device, vaginal pessaries or any medication prescribed for the treatment of urinary incontinence

Outcomes

Primary Outcomes

Effectiveness of combined duloxetine and PFMT with combined placebo and imitation PFMT in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

Effectiveness of combined duloxetine and PFMT with combined placebo and PFMT for up to 12 weeks in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

Secondary Outcomes

  • Incontinence Quality of Life scores from baseline to endpoint.
  • Symptoms Frequency & Bothersomeness.
  • Patient Global Impression - Impression at endpoint.
  • Percent change in weekly continence pad usage (CPAD) from baseline to endpoint.
  • Change in Patient Satisfaction Questionnaires -2 and -4 questionnaire scores from baseline to endpoint.
  • Percent change in daily CPAD from baseline to endpoint.
  • Compare safety of duloxetine with placebo based on vital signs , laboratory values and the occurrence of treatment-emergent adverse events.
  • Compare combined duloxetine and PFMT, combined duloxetine and imitation PFMT, combined placebo with PFMT and combined placebo and imitation PFMTwith respect to efficacy and to safety.
  • Compare the effect of duloxetine and placebo on patient compliance to PFMT and imitation PFMT regimes using a daly patient-generated log of completed contractions.
  • Generate long-term safety data (during open-label extension) on duloxetine in the treatment of women with SUI.

Investigators

Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials